User login
Key clinical point: Duration of endocrine therapy (ET) is an important risk factor for cognitive function impairment in patients with breast cancer (BC).
Major finding: Duration of ET was a significant risk factor for overall cognitive decline (odds ratio 1.296; 95% CI 1.008-1.665), with the prolongation of ET further increasing the risk for cognitive decline (linear-by-linear association test statistic 5.872; P < .05).
Study details: Findings are from a prospective, interventional single-center study including 127 women with BC, of which 49 patients were classified into the cognitive decline group.
Disclosures: This study was supported by Shanghai Science and Technology Innovation Action Plan and other sources. The authors declared no conflicts of interest.
Source: Yin Y et al. Association between endocrine therapy and cognitive decline in breast cancer based on propensity score matching. Front Med. 2023;10:1132287 (Jan 26). Doi: 10.3389/fmed.2023.1132287
Key clinical point: Duration of endocrine therapy (ET) is an important risk factor for cognitive function impairment in patients with breast cancer (BC).
Major finding: Duration of ET was a significant risk factor for overall cognitive decline (odds ratio 1.296; 95% CI 1.008-1.665), with the prolongation of ET further increasing the risk for cognitive decline (linear-by-linear association test statistic 5.872; P < .05).
Study details: Findings are from a prospective, interventional single-center study including 127 women with BC, of which 49 patients were classified into the cognitive decline group.
Disclosures: This study was supported by Shanghai Science and Technology Innovation Action Plan and other sources. The authors declared no conflicts of interest.
Source: Yin Y et al. Association between endocrine therapy and cognitive decline in breast cancer based on propensity score matching. Front Med. 2023;10:1132287 (Jan 26). Doi: 10.3389/fmed.2023.1132287
Key clinical point: Duration of endocrine therapy (ET) is an important risk factor for cognitive function impairment in patients with breast cancer (BC).
Major finding: Duration of ET was a significant risk factor for overall cognitive decline (odds ratio 1.296; 95% CI 1.008-1.665), with the prolongation of ET further increasing the risk for cognitive decline (linear-by-linear association test statistic 5.872; P < .05).
Study details: Findings are from a prospective, interventional single-center study including 127 women with BC, of which 49 patients were classified into the cognitive decline group.
Disclosures: This study was supported by Shanghai Science and Technology Innovation Action Plan and other sources. The authors declared no conflicts of interest.
Source: Yin Y et al. Association between endocrine therapy and cognitive decline in breast cancer based on propensity score matching. Front Med. 2023;10:1132287 (Jan 26). Doi: 10.3389/fmed.2023.1132287